Navigation Links
CeNeS in Medical Technology

Independent publication supports the profile of CeNeS phase II compound, CNS 5161

CAMBRIDGE, England, 4th May 2007 - CeNeS Pharmaceuticals plc (LSE: CEN), the Cambridge based biopharmaceutical company, notes the publication of an independent study in the respected scientific journal 'Synapse'* on its Phase II NMDA antagonist, CNS 5161. CeNeS is developing CNS 5161 as a potentia...

Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme

CAMBRIDGE, U.K. 2nd July 2007 - CeNeS Pharmaceuticals (AIM:CEN) ("CeNeS" or "the Company") the Cambridge-based biopharmaceutical company today announced that a paper published this week in CNS Drugs(1) further supports the hypothesis that a catechol-O-methyltransferase (COMT) inhibitor that acts i...

CeNeS Pharmaceuticals plc: Update on Successful Phase III results announced on Lead Product M6G

...rative pain CAMBRIDGE, England, 7th March 2007 - cenes Pharmaceuticals plc (AIM: CEN), the Cambridge base...ts The additional secondary data now received by cenes shows that: * less anti-emetic drugs (drugs used...mproved patient comfort due to lower PONV supports cenes justification of a substantial price premium for M...

CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006

...6G underway CAMBRIDGE, England, March 28, 2007 - cenes Pharmaceuticals plc ("CeNeS" or "the Company"), th...near-term." For more information please contact: cenes Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)12...n/Emma Thompson Tel: + 44 (0) 207 831 3113 About cenes Pharmaceuticals...

FDA approves IND on Lead Product M6G

... CAMBRIDGE, England, 26th April 2007 - cenes Pharmaceuticals plc (LSE: CEN), the Cambridge base...y analysis before progressing to Phase III trials. cenes is currently completing the protocol design of the...e therapy." For more information please contact: cenes Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)12...

Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits

...pared to morphine Cambridge, UK, 8th June 2007 - cenes Pharmaceuticals plc (AIM: CEN), the Cambridge base...in market." For more information please contact: cenes Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)12...n/Emma Thompson Tel: + 44 (0) 207 831 3113 About cenes Pharmaceuticals...
Other Tags
(Date:3/28/2015)... 28, 2015 How best to treat ... field in orthopaedic medicine. While diagnostic hip injections are ... the pain etiology, research presented today at the American ... Day suggests that pain relief from this diagnostic injection ... , “Our study looked to assess if the ...
(Date:3/28/2015)... NC (PRWEB) March 28, 2015 Genomic ... with peritoneal mesothelioma, revealing, for the first time, key ... Click here to read the newly posted story ... at the University of British Columbia, the British Columbia ... genome mapping to reveal underlying molecular alterations and mutations ...
(Date:3/28/2015)... 2015 Aureus Medical Group (web: ... physical therapy jobs, has announced that it will ... Therapy Association Annual Conference to be held April ... in Columbus, OH. , The OPTA Annual ... with products and services. , Representatives from ...
(Date:3/28/2015)... Viejo, California (PRWEB) March 28, 2015 ... announced a new overlay entitled Scratches 5K from Pixel ... grungy scratch effects to any media inside Final Cut ... Studios. “StoryBoard Corporate saves time and is an effective ... media using FCPX Overlay Scratches 5K's intuitive grunge overlays. ...
(Date:3/28/2015)... CA (PRWEB) March 28, 2015 ... specialists , this week released a report about the ... symptoms of asthma sufferers, and according to recent medical ... , According to the Environmental Protection Agency, people ... asthmatic reactions. Breathing in mold may trigger asthma attacks ...
Breaking Medicine News(10 mins):Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3
(Date:3/23/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ... announces its biometric payment technology, the Wocket® smart wallet, will ... 30 th . The new 30 ... markets. Gino Pereira , ... ad campaign following the recent initial shipment of Wocket smart ...
(Date:3/19/2015)... March 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... clip that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host ... way to pay, and ,a really big breakthrough in mobile ...
(Date:3/16/2015)... March 16, 2015 Between ... will present groundbreaking innovations in biometric identification at ... .      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ... innovation is well at the forefront: the company,s ... made in Germany . BiometricGate ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
Other Contents